PRESENTATION J.W., a 51-year-old African-American man, presented with fatigue, polyuria, and polydipsia. He was diagnosed with insulin-dependent diabetes mellitus 1 year ago when he presented with nonketotic hyperglycemic hyperosmolar syndrome. At the initial presentation, his blood glucose was 625 mg/dl, and his A1C was 18.9%. His adherence to a diabetes treatment, including basal and premeal insulin, was poor, which led to four different hospitalizations with hyperglycemic crises during the past year. His family history was unknown because he was adopted.
Subsequent laboratory studies done in the fasting condition revealed ferritin of 1,789 ng/ml, iron of 202 µg/dl, and transferrin of 276 µg/dl (calculated transferrin saturation of 73%); iron studies were repeated yielding similar results. Liver tests were significant for aspartate aminotransferase (AST) of 56 U/l and alanine aminotransferase (ALT) of 76 U/l, indicating mild elevation. Serological studies for chronic hepatitis demonstrated presence of hepatitis C (HCV), type 1b genotype. His C-peptide level was 0.7 ng/ml, and antibodies to GAD65 were not detected. Genetic testing for hereditary hemochromatosis (HH) showed that the patient was heterozygous for C282Y mutation (a carrier state). Hemoglobin electrophoresis did not reveal abnormal hemoglobin variants. Abdominal ultrasound demonstrated normal liver, spleen, and kidneys.
During the hospital stay, his condition improved, and his blood glucose significantly decreased after volume resuscitation and subcutaneous insulin therapy. He was discharged home with scheduled outpatient appointments. This patient had several admissions with hyperglycemic crises and a low basal C-peptide concentration, suggesting type 1 diabetes. However, there was no evidence of autoimmune involvement given the absence of GAD65 antibodies. Diabetic subjects with a history of hyperglycemic crises, negative autoimmune markers, and low insulin secretion (defined as a basal C-peptide < 1 ng/dl) are classified as having type 1B, or atypical, diabetes.
QUESTIONS

2,3
Despite the absence of autoimmunity, almost 100% of subjects with type 1B diabetes require lifelong insulin therapy and are at risk of Both HCV infection and HH are associated with increased risk of developing diabetes. Diabetes is now recognized as one of the extra-hepatic manifestations of HCV infection. [4] [5] [6] People with chronic HCV infection have a two-to fourfold higher likelihood of developing diabetes than nondiabetic control subjects. On the other hand, the prevalence of HCV infection is 2.5 times higher in patients with diabetes than in those without diabetes. 7 Prevalence of HCV infection is disproportionate in U.S. minorities; non-Hispanic blacks are more prone to have HCV antibodies than whites or Hispanic whites. 8 Advanced liver disease appears to potentiate the diabetogenic action of infection because as many as half of all patients with HCV cirrhosis develop diabetes. The clinical phenotype of a patient with HCV infection and diabetes is characterized by onset of diabetes in the fifth or sixth decade of life, BMI < 30 kg/m 2 , lower cholesterol level, and advanced liver disease.
Multiple factors may contribute to the pathogenesis of diabetes in patients with HCV infection. 5, 6 Insulin resistance is a core defect in development of HCV-associated diabetes. Increasing evidence indicates that decreased insulin action in the liver is caused by hepatic steatosis/ fibrosis and surge in proinflammatory cytokines tumor necrosis factor (TNF)=α and interleukin-6, as well as impaired insulin action in peripheral tissues, primarily muscle, largely underlined by TNF-α effects. Autoimmunity and α-cell cytopathic mechanism are unlikely to represent a primary mechanism in the pathogenesis of diabetes in HCV infection. Based on available clinical evidence, testing is recommended for HCV in individuals with diabetes and elevated liver enzymes (AST and ALT). 9 "Bronze diabetes" (diabetes related to iron-caused damage to the pancreas and characterized by a bronze skin tone caused by excess iron) has been considered a cardinal clinical manifestation of HH. Recent advances in genetic testing have elucidated that homozygosity of HFE gene mutation on single amino acid substitution in a certain position may lead to a severe tissue iron overload and the characteristic HH phenotype. 10 It has been suggested that three key mechanisms could mediate iron-induced diabetes: insulin deficiency, insulin resistance, and hepatic dysfunction. 11 Iron overload can overwhelm antioxidant defense systems in pancreas and peripheral tissues, thereby promoting defects in insulin secretion and insulin effects, respectively.
Heterozygosity of HFE gene on C282Y or H63D mutation is unlikely to result in end-organ dysfunction, liver disease, or diabetes, but it may predispose to a significant iron overload in the presence of associated comorbidities, such as chronic HCV or alcohol use.
12 Recent population studies have demonstrated a frequency of HFE gene mutation in different racial cohorts. In the United States, C282Y homozygosity is present in 0.4% of whites, 0.01-0.03% of African Americans, and 0.027% in Mexican Americans; heterozygosity for C282Y mutation is identified in almost 10% of whites and 2% of African Americans. [10] [11] [12] [13] Progress in HH screening and genetics translates to an early diagnosis and therapy of this disease. Screening for HH is only initiated if there is high clinical suspicion for this condition. Fasting transferrin saturation > 45-50% and ferritin level > 200 µg/l in women and > 300 µg/l in men is an indication for HFE genotype testing. 10 Recent studies, however, have shown that the prevalence of diabetes in patients with HH may not differ from that in the general population. 14, 15 Thus, it has not been clear whether screening for HH should be performed in patients with diabetes.
Hahn et al. 16 studied 3,500 white subjects with diabetes and found evidence of iron overload in 35 subjects, or 1% of the cohort, five of whom eventually were confirmed with having HH. The authors therefore emphasized the cost-effectiveness of screening of patients with diabetes for HH. Interestingly, it has also been suggested that C282Y genotype may predispose to higher risk of developing acute or chronic HCV infection. 17 Our patient demonstrated the iron overload phenotype, which likely occurred in the presence of both HCV infection and HFE gene mutation.
No previous studies have reported on the prevalence of HCV infection or HH in patients with type 1B or idiopathic diabetes. HCV infection increases the risk of developing type 2 diabetes by twoto fourfold because of increased insulin resistance, both in the liver and in peripheral tissues. Similarly, iron overload and HH may also lead to end-organ damage and increased risk of type 2 diabetes because of hepatic and peripheral insulin resistance and impaired insulin secretion.
No retrospective or prospective clinical studies have investigated the presence of the coexisting HCV infection and HFE gene mutation in patients with idiopathic type 1B diabetes. However, given the high prevalence of these conditions, epidemiological studies are needed to elucidate a potential association between diabetes, chronic HCV infection, and HH gene mutation.
It is possible that longstanding hyperglycemia in our patient may have resulted in β-cell dysfunction. This concept is known as glucose toxicity or glucose desensitization. 18, 19 Human studies have shown convincingly that β-cell function improves after chronic hyperglycemia is relieved by successful diabetes therapy. 20 Although the pathogenesis of glucose desensitization is not completely understood, it appears that chronic hyperglycemia induces a generalized downregulation of the glucose processing system that, at the level of the pancreas, may lead to impaired β-cell function and insulinopenia. The "blindness" of β-cells to glucose stimulation during sustained hyperglycemia may involve a reduction in the insulin and pancreatic duodenal homeobox factor-1 (PDX-1) gene expression.
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PDX-1 is a key transcriptional factor that regulates gene transcription in response to glucose. Thus, the putative role of glucose-induced β-cell desensitization has broad implications for the management of patients with decompensated diabetes and implies not only that hyperglycemia may be a consequence of altered β-cell function, but also, more importantly, that hyperglycemia might be an important etiological factor in the pathogenesis of metabolic decompensation. 
CLINICAL PEARLS
